The company said it will seek an expanded indication for the left atrial appendage closure device after it met all safety and ...

Study suggests a path forward for device therapy, though caveats are plenty ...

Data highlights the WATCHMAN FLX device provided statistically superior protection from bleeding, demonstrated similar efficacy compared to blood thinners in patients with non-valvular atrial fibrilla ...

Physicians wrestled with endpoint composition, low event rates, a possible difference in ischemic strokes, and more.

CHAMPION-AF shows Boston Scientific's Watchman FLX as a safe, effective first-line option for stroke risk reduction in ...

For patients with nonvalvular atrial fibrillation (AFib) who had no contraindications to taking oral anticoagulants, the use ...

In one of the largest studies of its kind, a trial of Boston Scientific’s small, permanent cardiac implant showed that it could potentially serve as an alternative to long-term blood thin | Boston ...

Boston Scientific (NYSE:BSX) announced new findings from the CHAMPION-AF trial supporting its Watchman FLX system.

SAN FRANCISCO — Thirteen months after percutaneous left atrial appendage closure (LAAC), outcomes did not differ whether closure was performed using the Amulet (Abbott Cardiovascular) or the Watchman ...

Please provide your email address to receive an email when new articles are posted on . In a head-to-head trial of the Amplatzer Amulet and Watchman FLX left atrial appendage closure devices, the ...

Please provide your email address to receive an email when new articles are posted on . In a real-world analysis of registry data, researchers also found that the Watchman FLX device (Boston ...